127 related articles for article (PubMed ID: 1869970)
1. Noninvasive grading of musculoskeletal tumors using PET.
Adler LP; Blair HF; Makley JT; Williams RP; Joyce MJ; Leisure G; al-Kaisi N; Miraldi F
J Nucl Med; 1991 Aug; 32(8):1508-12. PubMed ID: 1869970
[TBL] [Abstract][Full Text] [Related]
2. Fluorine-18-fluorodeoxyglucose PET imaging of soft-tissue sarcoma.
Nieweg OE; Pruim J; van Ginkel RJ; Hoekstra HJ; Paans AM; Molenaar WM; Koops HS; Vaalburg W
J Nucl Med; 1996 Feb; 37(2):257-61. PubMed ID: 8667056
[TBL] [Abstract][Full Text] [Related]
3. Comparison of fluorine-18-fluorodeoxyglucose and carbon-11-methionine PET in detection of malignant tumors.
Inoue T; Kim EE; Wong FC; Yang DJ; Bassa P; Wong WH; Korkmaz M; Tansey W; Hicks K; Podoloff DA
J Nucl Med; 1996 Sep; 37(9):1472-6. PubMed ID: 8790196
[TBL] [Abstract][Full Text] [Related]
4. Imaging bone and soft tissue tumors with the proliferation marker [18F]fluorodeoxythymidine.
Buck AK; Herrmann K; Büschenfelde CM; Juweid ME; Bischoff M; Glatting G; Weirich G; Möller P; Wester HJ; Scheidhauer K; Dechow T; Peschel C; Schwaiger M; Reske SN
Clin Cancer Res; 2008 May; 14(10):2970-7. PubMed ID: 18445694
[TBL] [Abstract][Full Text] [Related]
5. FDG-PET for evaluating musculoskeletal tumors: a review.
Aoki J; Endo K; Watanabe H; Shinozaki T; Yanagawa T; Ahmed AR; Takagishi K
J Orthop Sci; 2003; 8(3):435-41. PubMed ID: 12768492
[TBL] [Abstract][Full Text] [Related]
6. Benign versus malignant intraosseous lesions: discrimination by means of PET with 2-[F-18]fluoro-2-deoxy-D-glucose.
Dehdashti F; Siegel BA; Griffeth LK; Fusselman MJ; Trask DD; McGuire AH; McGuire DJ
Radiology; 1996 Jul; 200(1):243-7. PubMed ID: 8657920
[TBL] [Abstract][Full Text] [Related]
7. Metabolic imaging of human extremity musculoskeletal tumors by PET.
Kern KA; Brunetti A; Norton JA; Chang AE; Malawer M; Lack E; Finn RD; Rosenberg SA; Larson SM
J Nucl Med; 1988 Feb; 29(2):181-6. PubMed ID: 2831318
[TBL] [Abstract][Full Text] [Related]
8. Monitoring of neoadjuvant therapy response of soft-tissue and musculoskeletal sarcoma using fluorine-18-FDG PET.
Jones DN; McCowage GB; Sostman HD; Brizel DM; Layfield L; Charles HC; Dewhirst MW; Prescott DM; Friedman HS; Harrelson JM; Scully SP; Coleman RE
J Nucl Med; 1996 Sep; 37(9):1438-44. PubMed ID: 8790188
[TBL] [Abstract][Full Text] [Related]
9. Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-[F-18]fluoro-D-glucose.
Shreve PD; Grossman HB; Gross MD; Wahl RL
Radiology; 1996 Jun; 199(3):751-6. PubMed ID: 8638000
[TBL] [Abstract][Full Text] [Related]
10. Grading liposarcomas with PET using [18F]FDG.
Adler LP; Blair HF; Williams RP; Pathria MN; Makley JT; Joyce MJ; al-Kaisi N; Miraldi F
J Comput Assist Tomogr; 1990; 14(6):960-2. PubMed ID: 2229575
[TBL] [Abstract][Full Text] [Related]
11. Assessment of soft tissue lesions suspicious for liposarcoma by F18-deoxyglucose (FDG) positron emission tomography (PET).
Schwarzbach MH; Dimitrakopoulou-Strauss A; Mechtersheimer G; Hinz U; Willeke F; Cardona S; Attigah N; Strauss LG; Herfarth C; Lehnert T
Anticancer Res; 2001; 21(5):3609-14. PubMed ID: 11848531
[TBL] [Abstract][Full Text] [Related]
12. PET evaluation of soft-tissue masses with fluorine-18 fluoro-2-deoxy-D-glucose.
Griffeth LK; Dehdashti F; McGuire AH; McGuire DJ; Perry DJ; Moerlein SM; Siegel BA
Radiology; 1992 Jan; 182(1):185-94. PubMed ID: 1727280
[TBL] [Abstract][Full Text] [Related]
13. Fluorodeoxyglucose positron emission tomography of soft tissue tumours: is a non-invasive determination of biological activity possible?
Schulte M; Brecht-Krauss D; Heymer B; Guhlmann A; Hartwig E; Sarkar MR; Diederichs CG; Schultheiss M; Kotzerke J; Reske SN
Eur J Nucl Med; 1999 Jun; 26(6):599-605. PubMed ID: 10369945
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Limitations of F-18-fluoro-2-deoxy-D-glucose Positron Emission Tomography to Differentiate Between Malignant and Benign Bone and Soft Tissue Tumors.
Miwa S; Mochizuki T; Yamamoto N; Shirai T; Hayashi K; Takeuchi A; Inatani H; Igarashi K; Higuchi T; Abe K; Taniguchi Y; Aiba H; Ikeda H; Tsuchiya H
Anticancer Res; 2018 Jul; 38(7):4065-4072. PubMed ID: 29970532
[TBL] [Abstract][Full Text] [Related]
15. Detection of malignancies with SPECT versus PET, with 2-[fluorine-18]fluoro-2-deoxy-D-glucose.
Martin WH; Delbeke D; Patton JA; Sandler MP
Radiology; 1996 Jan; 198(1):225-31. PubMed ID: 8539384
[TBL] [Abstract][Full Text] [Related]
16. Neoplasms in a pediatric population: 2-[F-18]-fluoro-2-deoxy-D-glucose PET studies.
Shulkin BL; Mitchell DS; Ungar DR; Prakash D; Dole MG; Castle VP; Hernandez RJ; Koeppe RA; Hutchinson RJ
Radiology; 1995 Feb; 194(2):495-500. PubMed ID: 7824731
[TBL] [Abstract][Full Text] [Related]
17. Uptake of carbon-11-methionine and fluorodeoxyglucose in non-Hodgkin's lymphoma: a PET study.
Leskinen-Kallio S; Ruotsalainen U; Någren K; Teräs M; Joensuu H
J Nucl Med; 1991 Jun; 32(6):1211-8. PubMed ID: 2045935
[TBL] [Abstract][Full Text] [Related]
18. Glucose metabolic analysis of musculoskeletal tumours using 18fluorine-FDG PET as an aid to preoperative planning.
Watanabe H; Shinozaki T; Yanagawa T; Aoki J; Tokunaga M; Inoue T; Endo K; Mohara S; Sano K; Takagishi K
J Bone Joint Surg Br; 2000 Jul; 82(5):760-7. PubMed ID: 10963181
[TBL] [Abstract][Full Text] [Related]
19. Value of fluorine-18-FDG-PET to monitor hepatocellular carcinoma after interventional therapy.
Torizuka T; Tamaki N; Inokuma T; Magata Y; Yonekura Y; Tanaka A; Yamaoka Y; Yamamoto K; Konishi J
J Nucl Med; 1994 Dec; 35(12):1965-9. PubMed ID: 7989978
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of breast masses and axillary lymph nodes with [F-18] 2-deoxy-2-fluoro-D-glucose PET.
Adler LP; Crowe JP; al-Kaisi NK; Sunshine JL
Radiology; 1993 Jun; 187(3):743-50. PubMed ID: 8497624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
